Study evaluates the safety and effectiveness of the OMNYPULSE™ Platform in Europe and Canada Irvine, CA – August 26, 2024 – Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech,i announced the enrollment completion of the Omny-IRE clinical trial. Omny-IRE is a prospective, multi-center, […]

Irvine, CA – May 17, 2024 – Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announced late-breaking results from the pivotal phase of the admIRE pivotal clinical trial, plus additional results from the VIRTUE study, presented at the Heart Rhythm Society (HRS) […]

New CARTO™ 3 System Version 8 software introduces machine learning capabilities Increases efficiency, reproducibility, and accuracyi in the electro-anatomical maps  electrophysiologists use in catheter ablation procedures Irvine, CA – May 8, 2024 – Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, announces the […]

Irvine, CA (April 9, 2024) – Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech, today announced three-month follow-up results from the SmartfIRE clinical trial, unveiled in a late-breaking presentation by Dr. Tom De Potter,i an investigator in the study, during the annual meeting […]

Regulatory approval for the first fully integrated PFA system with a CARTO-enabled simple and reproducible workflow. Integrated with the world’s leading CARTO™ 3D Cardiac Mapping System for the treatment of symptomatic drug refractory recurrent paroxysmal atrial fibrillation (AF). CE Mark…

Irvine, CA – February 27, 2024 – Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTech[i], announced the commencement of patient cases with the investigational Laminar Left Atrial Appendage Elimination (LAAX) System as part of its pivotal investigational device exemption (IDE) study. […]

Irvine, CA – February 8, 2024 – Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi, today announced support for two collaborative studies, VIRTUE and POLARIS. These studies aim to better understand the use and workflows with the investigational VARIPULSE™ Platform for treating […]

Retrospective Analysis of Real-World Data Presented as Late-Breaker at 29th Annual International AF Symposium  Irvine, CA – February 1, 2024 – Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTechi, revealed findings from a company-funded study of real-world data. Titled “Real-world Data Affirms […]

Final results from inspIRE study demonstrate 80% freedom from atrial arrhythmia recurrence at 12 months in patients with optimal Pulsed Field Ablation applications First look results from admIRE study suggests similar outcomes Irvine, CA – February 2, 2024 – Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part […]